AI Article Synopsis
- The study investigates the effectiveness of a single-pill fixed-dose combination of valsartan (an angiotensin II type 1 receptor blocker) and amlodipine (a calcium channel blocker) for treating hypertension.
- Thirty-five patients with uncontrolled blood pressure were divided into two treatment groups: one receiving both medications in a single pill (VA group) and the other receiving valsartan in the morning and nifedipine at night (VN group) for 16 weeks.
- Results showed that the VN group had lower morning diastolic blood pressure and required fewer dose adjustments compared to the VA group, indicating better overall effectiveness in BP control and kidney protection.
Article Abstract
Background: It is controversial whether a single-pill fixed-dose combination of angiotensin II type 1 receptor blocker and calcium channel blocker (CCB) is effective for all types of hypertension.
Methods: Thirty-five patients with uncontrolled blood pressure (BP) under treatment with valsartan 80 mg/day or amlodipine 5 mg/day were enrolled. They were randomly divided into two treatment groups: a single-pill fixed-dose combination of valsartan 80 mg/day and amlodipine 5 mg/day in the morning (VA group), or valsartan 80 mg/day in the morning and nifedipine CR 20 mg/day at night (VN group), and treated for 16 weeks. If the patient did not reach the target office BP at 8 weeks, they received double doses of CCBs.
Results: In the VN group, morning diastolic BP was significantly lower than the respective values in the VA group at 8 weeks. The percentage of patients who required a double dose of CCB in the VN group was significantly lower than that in the VA group. At 16 weeks, the BP levels in both groups were significantly reduced. Urinary albumin/creatinine at 16 weeks was significantly less than that at 0 weeks in the VN group.
Conclusion: Combination therapy with valsartan and nifedipine CR may help to control morning BP and protect the kidneys.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808261 | PMC |
| http://dx.doi.org/10.4021/jocmr1563w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation.
Cureus
October 2024
Department of Cardiology, National Hospital Organization (NHO) Hiroshimanishi Medical Center, Otake, JPN.
Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF.
View Article and Find Full Text PDFSerum uric acid-lowering effect of sacubitril/valsartan in hypertensive patients: evaluation by switching from angiotensin II receptor blockers.
Blood Press Monit
December 2024
Department of Cardiovascular Medicine, Ishikiriseiki Hospital, Higashiosaka.
Objective: Since hyperuricemia is a risk factor for cardiovascular disease and chronic kidney disease, it is necessary to pay attention to trends in uric acid levels when treating hypertensive patients with drugs. The present study investigated the effect of switching from angiotensin II receptor blocker (ARB) to sacubitril/valsartan on serum uric acid levels in treated hypertensive patients and further examined what factors could be associated with its effect.
Methods: In 75 hypertensive patients under treatment with at least one antihypertensive agent including ARB, clinic blood pressure and biochemical parameters were assessed before and after drug switching to sacubitril/valsartan (200 mg/day).
Wastewater-based epidemiology to assess pharmaceutical consumption. Spanish perspective.
Sci Total Environ
November 2024
Universitat Rovira i Virgili, Department of Analytical Chemistry and Organic Chemistry, Tarragona, Spain.
Wastewater-based epidemiology (WBE) is a well-established approach that can provide objective and real-time data on the consumption of substances such as pharmaceuticals. However, most of the studies reported so far compares consumption data obtained using WBE with those derived from prescription data from public health systems, which is often incomplete and might represent a source of uncertainty. This study aims to compare the measured pharmaceutical consumption back calculated with the WBE approach with consumption derived from dispensed pharmaceuticals in two regions of Spain, managed by two different Health Systems.
View Article and Find Full Text PDFSacubitril/Valsartan Improves Cardiac Function in Dialysis Patients.
Cureus
June 2024
Cardiology, Edinburgh Medical Missionary Society (EMMS) Nazareth Hospital, Nazareth, ISR.
Heart failure (HF) is characterized by the activation of adverse neurohormonal systems and a high mortality rate. Noteworthy, HF is a well-known complication of chronic kidney disease (CKD), especially in end-stage kidney disease (ESKD), where dialysis patients are seven to eight times more likely to encounter cardiac arrest than the general population. Therefore, it is important to develop efficient treatments to improve cardiac function in dialysis patients and eventually reduce the cardiovascular death toll.
View Article and Find Full Text PDFClinical Benefit of Sacubitril/Valsartan for Hypertensive Patients in Daily Practice and Predictors of Its Antihypertensive Effect.
Circ Rep
July 2024
Department of Cardiovascular Medicine, Ishikiriseiki Hospital Osaka Japan.
The blood pressure (BP)-lowering effect of sacubitril/valsartan (Sac/Val) is greater than that of angiotensin II receptor blockers (ARBs) but in in real-world clinical practice, Sac/Val is used in a variety of patterns other than switching from ARBs. In the present study we investigated the effects of Sac/Val on BP and biochemical parameters when switching from or adding it to various antihypertensive drugs and examined what factors could be predictors of the antihypertensive effect of Sac/Val. In 108 hypertensive patients treated with antihypertensive agents (including 4 naïve cases), clinic BP and various biochemical parameters were assessed before and after switching to/adding Sac/Val (200 mg/day).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!